Cargando…

NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas

Glioma is the most common malignant primary brain tumor diagnosed in adults. Current therapies are unable to improve its clinical prognosis, imposing the need for innovative therapeutic approaches. The main reason for the poor prognosis is the great cell heterogeneity of the tumor and its immunosupp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Changqing, Zhai, You, Li, Guanzhang, Jiang, Tao, Zhang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576093/ https://www.ncbi.nlm.nih.gov/pubmed/34765554 http://dx.doi.org/10.3389/fonc.2021.751183

Ejemplares similares

A novel gene signature based on five immune checkpoint genes predicts the survival of glioma
por: Zhang, Wei, et al.
Publicado: (2021)

Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia
por: Wang, Zong-Han, et al.
Publicado: (2023)

Novel Immunotherapy Options for Extranodal NK/T-Cell Lymphoma
por: Hu, Boyu, et al.
Publicado: (2018)

CAR-NK Cell: A New Paradigm in Tumor Immunotherapy
por: Marofi, Faroogh, et al.
Publicado: (2021)

Interactions Between Nanoparticles and Dendritic Cells: From the Perspective of Cancer Immunotherapy
por: Jia, Jianbo, et al.
Publicado: (2018)

T-Cell Immunotherapy for Pediatric High-Grade Gliomas: New Insights to Overcoming Therapeutic Challenges
por: Haydar, Dalia, et al.
Publicado: (2021)

CRISPR Gene Editing of Human Primary NK and T Cells for Cancer Immunotherapy
por: Elmas, Ezgi, et al.
Publicado: (2022)

Retraction: CAR-NK Cell: a new paradigm in tumor immunotherapy
Publicado: (2023)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

DNA damage response and evasion from immunosurveillance in CLL: new options for NK cell-based immunotherapies
por: Shatnyeva, Olga M., et al.
Publicado: (2015)

Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion
por: Li, Guanzhang, et al.
Publicado: (2021)

Heightened metabolic responses in NK cells from patients with neuroblastoma suggests increased potential for immunotherapy
por: Slattery, Karen, et al.
Publicado: (2022)

Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma
por: Petersen, Christopher T., et al.
Publicado: (2019)

Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples
por: Di, Wang, et al.
Publicado: (2021)

Mining the Gut Microbiota for Microbial-Based Therapeutic Strategies in Cancer Immunotherapy
por: Li, Bolei, et al.
Publicado: (2021)

NK cell-based tumor immunotherapy
por: Zhang, Hao, et al.
Publicado: (2023)

Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)

A novel DNA repair‐related nomogram predicts survival in low‐grade gliomas
por: Li, Guanzhang, et al.
Publicado: (2020)

DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker
por: Zhang, Jingwen, et al.
Publicado: (2021)

TREM2 is associated with tumor immunity and implies poor prognosis in glioma
por: Yu, Mingchen, et al.
Publicado: (2023)

Durable Response to Sintilimab and Chidamide in a Patient With Pegaspargase- and Immunotherapy-Resistant NK/T-Cell Lymphoma: Case Report and Literature Review
por: Yan, Zheng, et al.
Publicado: (2020)

Corrigendum: Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer
por: Peng, Yurong, et al.
Publicado: (2023)

Single-Cell RNA-Sequencing Shift in the Interaction Pattern Between Glioma Stem Cells and Immune Cells During Tumorigenesis
por: Zhai, You, et al.
Publicado: (2020)

Knowledge structure and hotspots research of glioma immunotherapy: a bibliometric analysis
por: Yuan, Yexin, et al.
Publicado: (2023)

Redox Regulator GLRX Is Associated With Tumor Immunity in Glioma
por: Chang, Yuanhao, et al.
Publicado: (2020)

Clinical Diagnosis and Perioperative Management of Glioma-Related Epilepsy
por: You, Gan, et al.
Publicado: (2021)

Immunomodulation of NK Cells by Ionizing Radiation
por: Chen, Jiarui, et al.
Publicado: (2020)

A novel chemokine‐based signature for prediction of prognosis and therapeutic response in glioma
por: Fan, Wenhua, et al.
Publicado: (2022)

The Function of NK Cells in Tumor Metastasis and NK Cell-Based Immunotherapy
por: Yu, Yanlin
Publicado: (2023)

NK Cell-Based Glioblastoma Immunotherapy
por: Golán, Irene, et al.
Publicado: (2018)

NK Cell-Based Immunotherapies in Cancer
por: Shin, Min Hwa, et al.
Publicado: (2020)

Immunotherapy for Cutaneous Squamous Cell Carcinoma: Results and Perspectives
por: Alberti, Andrea, et al.
Publicado: (2022)

Kill and Clearance in HCC: An Approach Based on NK Cells and Macrophages
por: Mehrabi, Maryam, et al.
Publicado: (2021)

Ferroptosis: A novel therapeutic strategy and mechanism of action in glioma
por: Zhang, Gaosen, et al.
Publicado: (2022)

Valproic Acid: A Promising Therapeutic Agent in Glioma Treatment
por: Han, Wei, et al.
Publicado: (2021)

Dietary fungi in cancer immunotherapy: From the perspective of gut microbiota
por: Wei, Yibing, et al.
Publicado: (2023)

The Advances and Challenges of NK Cell-Based Cancer Immunotherapy
por: Kang, Synat, et al.
Publicado: (2021)

An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas
por: Li, Guanzhang, et al.
Publicado: (2022)

Role of B7 family members in glioma: Promising new targets for tumor immunotherapy
por: Wang, Yan, et al.
Publicado: (2023)

Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy
por: He, Yuqing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ccdtnp005o9ae4764re5n80rc6